All In Biotech

Drug Trial Radar · NCT02038036

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)

Last checked: Nov 20, 2026Latest source record: Jul 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

149

Actual

Start

Mar 25, 2014

Primary completion

Sep 29, 2015

Study completion Apr 7, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 16, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compared the efficacy and safety of ruxolitinib to Best Available Therapy (BAT) in patients with polycythemia vera (PV) who were hydroxyurea (HU) resistant or intolerant and did not have a palpable spleen.

Conditions

  • Polycythemia Vera

Interventions

  • Best Available TherapyDrug

    Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.

  • RuxolitinibDrug

    Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Achieving Hematocrit (Hct) Control at Week 28Time frame: Week 28

Locations

48 sites in 12 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Herston, Queensland, Australia

  • Novartis Investigative Site

    Antwerp, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Bayonne, Bayonne Cedex, France

  • Novartis Investigative Site

    Augsburg, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Jena, Germany

  • Novartis Investigative Site

    Leipzig, Germany

  • Novartis Investigative Site

    Magdeburg, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Minden, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Debrecen, Hungary

  • Novartis Investigative Site

    Kaposvár, Hungary

  • Novartis Investigative Site

    Mumbai, Maharashtra, India

  • Novartis Investigative Site

    Vellore, Tamil Nadu, India

  • Novartis Investigative Site

    Nahariya, Israel

  • Novartis Investigative Site

    Netanya, Israel

  • Novartis Investigative Site

    Tel Aviv, Israel

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Florence, FI, Italy

  • Novartis Investigative Site

    Rome, Lazio, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Pavia, PV, Italy

  • Novartis Investigative Site

    Torino, TO, Italy

  • Novartis Investigative Site

    Varese, VA, Italy

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Málaga, Andalusia, Spain

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.